Compare OCSL & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | SLDB |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | 2017 |
| Metric | OCSL | SLDB |
|---|---|---|
| Price | $13.15 | $9.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $12.63 | ★ $16.36 |
| AVG Volume (30 Days) | 560.2K | ★ 876.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | N/A |
| P/E Ratio | $65.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.63 | $3.79 |
| 52 Week High | $14.31 | $11.45 |
| Indicator | OCSL | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 56.51 |
| Support Level | $12.31 | $5.21 |
| Resistance Level | $13.39 | $11.45 |
| Average True Range (ATR) | 0.27 | 0.43 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 90.64 | 67.25 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.